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only reviewed oncology orphans thereby resulting in inconsistent access. Alternative 
funding mechanisms sometimes provide a temporary reimbursement fix in the UK. 
Ex- factory pricing varied by country both at launch and over time. CONCLUSIONS: 
Significant differences exist between the number of orphan drug approvals and 
time to access in the US vs. EU. The US is notably faster than the EU5 and Germany 
is notably faster than other EU5 countries. For pricing, the US is not always the high 
price country. Furthermore, there appears to be an inverse relationship between size 
of the indicated patient population and reimbursed price.
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OBJECTIVES: To explore use of electronic medical records (EMR) for identifying driv-
ers of all-cause healthcare resource utilization and factors associated with increased 
resource use in patients with fibromyalgia (FM). METHODS: This retrospective 
analysis used structured de-identified EMR data from the Humedica database 
including demographics, clinical characteristics, healthcare resource utilization, 
and prescriptions. Adults (≥ 18 years) with FM were identified based on ≥ 2 ICD-9 
codes for FM (729.1) ≥ 30 days apart between January 1, 2008 and December 31, 2012, 
and were required to have ≥ 12 months continuous enrollment pre- and post-index; 
the first FM diagnosis was the index event. Multivariate analysis using generalized 
linear models evaluated how demographic and clinical characteristics relate to 
12-month post-index resource utilization. RESULTS: Patients were predominantly 
female (81.4%), Caucasian (87.7%), with a mean±SD age of 54.4±14.8 years. Primary 
drivers of resource utilization were “medication orders” and “physician office visits,” 
used by 91.6% and 87.5% of patients, respectively, with 12-month post-index means 
of 21±21.5 drug orders/patient and 15.1±18.1 office visits/patient, the latter account-
ing for 73.3% of all healthcare visits. Opioids were the most common prescrip-
tion medication, 44.3% of patients. The chance of being a high healthcare resource 
utilizer was significantly increased (p< 0.001) 1.26-fold among African-Americans 
relative to Caucasians and for patients with specific comorbid conditions ranging 
from 1.06-fold (musculoskeletal pain and depression/bipolar disorder) to 1.21-fold 
(congestive heart failure). Similarly, factors significantly (p< 0.001) associated with 
increased number of medications ordered included being female (1.23-fold) and 
the presence of conditions such as sleep disorders (1.08-fold), depression/bipolar 
disorder (1.07-fold), and anxiety (1.06-fold). CONCLUSIONS: Physician office visits 
and pharmacotherapy were drivers of all-cause healthcare utilization; opioids were 
the most commonly prescribed medication class. Comorbid conditions were key 
factors associated with high resource use. EMR can be a useful tool for identifying 
and potentially managing FM patients with high healthcare resource utilization.
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OBJECTIVES: In this context, the challenge of this essay is to estimate the price elas-
ticity for soda and fruit drink in Brazil and the price effects on weight outcomes 
and obesity prevalence. METHODS: The elasticity was measured through a two-part 
model (TPM) estimated for all sample and different subgroups. The empirical model 
explains the quantities of SSB demanded as function of its prices and other variables. 
Considering the estimated elasticity, we converted the reduction on consumption into 
weight transforming the consumption elasticity from grams to kilocalories and then 
we applied a frequently used rule, which considers that a reduction of 3,500 calories 
induces a 0,450 kg loss in body weight, everything else remaining equal. RESULTS: 
Overall, the results display a smaller prevalence and lower consumption with higher 
prices. The TPM model predicts a reduction of 348.3g in weekly soda consumption 
and 4.5g of fruit drink to each one Real increased price. For all sample estimates, price 
elasticity is -0.61 for soda and -1.32 for fruit drinks, suggesting that a 20% increase in 
price was associated with a decline of soda and fruit drink in weekly consumption 
by 12.2% and 26.4%, respectively. This evidence shows a higher sensitivity to price 
changes for juice drinks than for soda, in spite of the higher consumption of soda. 
TConsidering that weight reductions, the prevalence of overweight among adults 
could decline from 48.13 to 47.75 percent and obesity prevalence could be reduced 
from 18.77 to 18.5 percent in one year. CONCLUSIONS: Our main findings suggest that 
tax policy might be an effective tool to reduce the soda and juice drink consumption 
and body weight. We also identified that subgroups who consume higher amounts 
of SSB are relatively more price sensitive and in these cases pricing policies have an 
expressive potential in reducing SSB consumption and body weight.
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OBJECTIVES: In 2006, the American College of Medical Genetics (ACMG) recom-
mended expanding NBS, relying largely on scoring from a stakeholder survey on 
19 attributes of 84 rare conditions. Points were scored according to mean answers 
from the responders. Sums of scores resulted in 3 different entry points into an 
algorithm (EPA) that determined ACMG final screening recommendations. This 
research examines one of the survey questions about condition incidence and 
compares the ACMG use of surveyed opinions versus the actual facts that they 
also report. METHODS: The report indicated each condition’s mean scores for 
survey questions. The incidence question scored 0-100 points. Very rare conditions 
ing BT alone (P< 0.001); patients receiving non-PSO concomitant medications were 
19% - 32% more likely to stay on their BT (p< 0.001) than those not receiving; and 
patients who switched BT were 2.35x more likely to stop BT within 24 months versus 
non-switchers (p< 0.001). Using a cost model, patients who switched BT had higher 
average annual costs of $4,355 and $3,679 in private and public plans respectively 
compared to those who didn’t switch (P< 0.001). CONCLUSIONS: 68% of PSO patients 
on BT either switch or stop therapy, indicating there remains an unmet need for 
new treatment options. In addition, switching is associated with significantly higher 
therapy costs. With better understanding of predictors for retention, patient support 
programs can be designed to address the specific needs of at-risk groups.
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OBJECTIVES: Both ultra orphan and cancer drugs are premium priced therapies with 
high annual per patient costs. The local legislation and reimbursement mechanisms 
have had significant impact on pricing trends for these therapies. The objectives 
of this analysis were to compare the price differential for ultra orphan and cancer 
drugs in the US and the UK, and understand the impact of local reimbursement 
mechanisms. METHODS: A set of 22 drugs (10 ultra orphan and 12 cancer drugs) 
was selected based on their availability in the US and the UK. The 2014 AWP, WAC 
and net prices were obtained for all 22 drugs. All UK prices were converted to USD. 
Primary discussions with ex-payer and policy experts were conducted to understand 
the basis and implication of the price differentials. RESULTS: For ten selected ultra 
orphan drugs, the median WAC price premium for the US compared to the UK net 
price was 10%. For 12 selected cancer drugs the median WAC price premium for 
the US compared to the UK net price was 106% (based on AWP the premiums were 
29% and 149%, respectively). Eight out of 10 ultra orphan and 12 out of 12 cancer 
drugs were higher priced in the US compared to the UK. Primary discussions with 
experts suggest the role of legislation for coverage of cancer drugs in the US and 
special coverage of rare disease products in the UK and reimbursement mechanisms 
(use of cost effectiveness driven HTAs in the UK and the use of co-pay in the US) 
as primary drivers of high price differential for cancer drugs versus ultra orphan 
therapies. CONCLUSIONS: The local reimbursement mechanisms are major driv-
ers of price differential for ultra orphan and cancer drugs in the US and the UK.
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OBJECTIVES: Pharmaceutical manufacturers can apply to the US Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) for orphan drug 
status for pharmaceuticals that treat rare medical conditions. This study compares 
the policies and processes that influence orphan drug designation in the US and the 
EU and examines the approval data to explain any differences and/or trends in deci-
sion making. METHODS: We conducted a quantitative analysis on the publicly avail-
able data on orphan drug approvals released by the FDA and EMA. By looking at the 
numbers of drugs approved each year, the drugs submitted and approved for orphan 
indications, and their relevant disease areas we were able to identify any trends 
and dissimilarities in the organizations final approval decisions. Following this, 
we performed qualitative research with a focused literature search of the Medline 
database and relevant websites, to explore the differences in policies and processes 
between the organizations that may have led to conflicting decisions. RESULTS: 
There were significant differences in the processes, policies and requirements for 
orphan drugs. The FDA consistently approved more orphan drugs each year dur-
ing 2002-2014 (when comparison data were available). However, the numbers of 
products accepted are converging (e.g. in 2005, the EMA approved approximately 
81% fewer orphan drugs; by 2013, this gap was 36%). Some differences in decisions 
were identified, largely due to different evidence requirements. CONCLUSIONS: 
The likelihood of a drug gaining orphan drug status in either the US or the EU is 
dependent on a number of different factors. If the trends persist, it is likely that the 
organizations will designate a similar number of products as orphan drugs each 
year, although the approved products may differ. These may affect which organiza-
tion manufacturers choose to submit applications to first.
PSY77
timing of eu5 & uS orPHan Drug aPProvalS anD Prma between 2009 
anD 2013
Mycka J.1, Dellamano R.2, Lobb W.1, Dalal N.1, Pereira E.1, Dellamano L.2, Sagaydachnaya O.1, 
Lue J.1
1Medical Marketing Economics LLC (MME), Montclair, NJ, USA, 2ValueVector, Milan, Italy
OBJECTIVES: To examine pricing, reimbursement and market access of orphan drugs 
approved by EMA and FDA between January 2009 and December 2013. METHODS: 
Analyzed the orphan drugs approved by both EMA and FDA between Jan 2009 and 
Dec 2013, by country (US & EU5) regarding; time to market, benefit evaluations, 
pricing and reimbursement differences, as well as any similarities or differences by 
size of population. RESULTS: In the time frame, 102 orphan drugs were approved in 
the US vs. just 31 by the EMA. Of those, only 13 orphan drugs were approved by both 
agencies. For these 13 drugs, approval took an average of 66 weeks from filing with 
the EMA and 45 weeks with the FDA. Average US time to launch from approval was 9 
weeks (only 2 weeks if one outlier is removed). In the EU, all 13 drugs were available 
and reimbursed on the German market in an average of 16 weeks while only 5 had 
completed P&R in Spain in an average of 97 weeks. Early access to reimbursement 
via the ATU program in France and L648 program in Italy was sometimes pursued. 
In the UK, SMC recommendations for orphan drugs were often negative, and NICE 
